NRx Pharmaceuticals (NRXP) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

NRXP Stock Forecast

NRx Pharmaceuticals stock forecast is as follows: an average price target of $2.00 (represents a 33.33% upside from NRXP’s last price of $1.50) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

NRXP Price Target

The average price target for NRx Pharmaceuticals (NRXP) is $2.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 33.33% upside from NRXP's last price of $1.50.

NRXP Analyst Ratings

Buy

According to 2 Wall Street analysts, NRx Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for NRXP stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

NRx Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 30, 2022	Vernon Bernardino	H.C. Wainwright	$2.00	$0.57	249.04%	33.33%

The latest NRx Pharmaceuticals stock forecast, released on Jun 30, 2022 by Vernon Bernardino from H.C. Wainwright, set a price target of $2.00, which represents a 249.04% increase from the stock price at the time of the forecast ($0.57), and a 33.33% increase from NRXP last price ($1.50).

NRx Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$1.50	$1.50	$1.50
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of NRx Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NRx Pharmaceuticals's last price of $1.50. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 21, 2024	EF Hutton		Buy	Initialise
Aug 02, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 30, 2022	H.C. Wainwright		Buy	Initialise

NRx Pharmaceuticals's last stock rating was published by EF Hutton on Oct 21, 2024. The company Initialise its NRXP rating from "null" to "Buy".

NRx Pharmaceuticals Financial Forecast

NRx Pharmaceuticals Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$274.08M	$263.53M	$263.53M	$252.99M	$134.84M	$129.66M	$129.66M	$124.47M	$46.87M	$45.07M	$45.07M	$43.27M	$25.00M	$20.00M	$10.00M	$5.00M	-	-	-
High Forecast	$274.08M	$263.53M	$263.53M	$252.99M	$134.84M	$129.66M	$129.66M	$124.47M	$46.87M	$45.07M	$45.07M	$43.27M	$25.00M	$20.00M	$10.00M	$5.00M	-	-	-
Low Forecast	$274.08M	$263.53M	$263.53M	$252.99M	$134.84M	$129.66M	$129.66M	$124.47M	$46.87M	$45.07M	$45.07M	$43.27M	$25.00M	$20.00M	$10.00M	$5.00M	-	-	-
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

NRx Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NRXP's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

NRx Pharmaceuticals EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict NRXP's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NRx Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

NRx Pharmaceuticals Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$24.76M	$23.83M	$23.86M	$22.93M	$11.51M	$11.07M	$11.09M	$10.65M	$3.14M	$3.02M	$3.02M	$2.90M	$1.74M	$1.09M	$-1.49M	$-3.38M	$-3.48M	$-6.09M	$-7.31M
High Forecast	$24.76M	$23.83M	$23.86M	$22.93M	$11.51M	$11.07M	$11.09M	$10.65M	$3.14M	$3.02M	$3.02M	$2.90M	$1.74M	$1.09M	$-1.49M	$-3.38M	$-3.48M	$-6.09M	$-7.31M
Low Forecast	$24.76M	$23.83M	$23.86M	$22.93M	$11.51M	$11.07M	$11.09M	$10.65M	$3.14M	$3.02M	$3.02M	$2.90M	$1.74M	$1.09M	$-1.49M	$-3.38M	$-3.48M	$-6.09M	$-7.31M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

NRx Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NRXP's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

NRx Pharmaceuticals SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

NRx Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NRXP last annual SG&A of $NaN (undefined).

NRx Pharmaceuticals EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$2.26	$2.17	$2.17	$2.09	$1.05	$1.01	$1.01	$0.97	$0.29	$0.28	$0.28	$0.26	$0.16	$0.10	$-0.14	$-0.31	$-0.32	$-0.56	$-0.69
High Forecast	$2.26	$2.17	$2.17	$2.09	$1.05	$1.01	$1.01	$0.97	$0.29	$0.28	$0.28	$0.26	$0.16	$0.10	$-0.14	$-0.31	$-0.32	$-0.56	$-0.69
Low Forecast	$2.26	$2.17	$2.17	$2.09	$1.05	$1.01	$1.01	$0.97	$0.29	$0.28	$0.28	$0.26	$0.16	$0.10	$-0.14	$-0.31	$-0.32	$-0.56	$-0.69
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, NRx Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NRXP previous annual EPS of $NaN (undefined).

NRx Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ADTX	Aditxt	$0.26	$160.00	61438.46%
LGVN	Longeveron	$1.78	$10.00	461.80%	Buy
NRXP	NRx Pharmaceuticals	$1.64	$2.00	21.95%	Buy

NRXP Forecast FAQ

Is NRx Pharmaceuticals a good buy?

Yes, according to 2 Wall Street analysts, NRx Pharmaceuticals (NRXP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of NRXP's total ratings.

What is NRXP's price target?

NRx Pharmaceuticals (NRXP) average price target is $2 with a range of $2 to $2, implying a 33.33% from its last price of $1.5. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will NRx Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for NRXP stock, the company can go up by 33.33% (from the last price of $1.5 to the average price target of $2), up by 33.33% based on the highest stock price target, and up by 33.33% based on the lowest stock price target.

Can NRx Pharmaceuticals stock reach $2?

NRXP's average twelve months analyst stock price target of $2 does not support the claim that NRx Pharmaceuticals can reach $2 in the near future.

What are NRx Pharmaceuticals's analysts' financial forecasts?

NRx Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $518.62M (high $518.62M, low $518.62M), average EBITDA is $0 (high $0, low $0), average net income is $44.32M (high $44.32M, low $44.32M), average SG&A $0 (high $0, low $0), and average EPS is $4.04 (high $4.04, low $4.04). NRXP's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $1.05B (high $1.05B, low $1.05B), average EBITDA is $0 (high $0, low $0), average net income is $95.39M (high $95.39M, low $95.39M), average SG&A $0 (high $0, low $0), and average EPS is $8.69 (high $8.69, low $8.69).